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Objectives . The goal of this study was to assess the hypothesis
that transdermal scopolamine would increase vagal activity in
patients after myocardial infarction .
Background. In postmyocardial infarction patients, low heart
rate variability and reduced baroreceptor reflex sensitivity are
associated with increased mortality. Accordingly, there is an
increasing interest in a mechanist for shifting the sympathovagal
balance toward vagal dominance
Methods. The effects of transdermal administration of scopol-
amine on heart rate variability and baroreceptor reflex sensitivity
were assessed in 20 patients (mean v;ge 59 ± 11 years) by
pharmacologic washout 14 ± 3 days after myocardial infarction .
Heart rate variability and baroreceptor reflex sensitivity were
measured 24 h after application of the scopolamine patch and
compared with the values measured before scopolamine and after
application of a placebo patch. The following variables were
derived from a 15-min electrocardiographic recording : the mean
RR interval and its standard deviation, the mean square succes-
sive difference, the percent of intervals differing >50 ms from the
preceding RR interval and the low and high frequency areas
resulting from power spectral analysis.
The potential beneficial effects of augmented vagal activity
during acute myocardial ischemia have received increasing
attention in the past several years (1-4) . Both experimental
(5-7) and clinical studies (8-10) indicate a strong correlation
between indexes of either impaired vagal reflexes or reduced
vagal tone and a greater incidence of sudden cardiac death .
Experiments performed in a conscious canine animal model
for sudden cardiac death (11) have indicated that a depressed
baroreflex sensitivity (5,6) and a reduced heart rate variabil-
ity (7) characterize subjects at high risk for the occurrence of
ventricular fibrillation . The experimental findings are closely
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Results. The placebo patch had no effect on the variables
measured. Scopolamine increased both heart rate variability and
baroreceptor reflex sensitivity significantly . Specifically, the mean
RR interval and its standard deviation increased by 7 .1% (p =
0.01) and 25% (p = 0.004), respectively . The mean square
successive difference increased by 38% (p = 0 .0003) and the
percent of intervals differing >50 Ins from the preceding interval
by 100% (p =- 0 .001) . The ratio of low to high frequency r of
the power spectrum decreased by 24% (p = 0.02), an. I : :a-
receptor reflex sensitivity increased by 42% (p =: 1MY TO e
effects were also evident in patients with very low initial values.
Side effects were minimal .
Conclusions . Transdermal scopolamine increased measures of
heart rate variability and baroreceptor reflex sensitivity in pa-
tients with a recent myocardial infarction toward values associ-
ated with a better prognosis . Pharmacologic modulation of the
autonomic balance by scopolamine or related drugs deserves
evaluation as a new and promising approach to reduce risk after
myocardial infarction .
(J Am Coll Cardiol 1993,22 :1327-34)
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paralleled by clinical studies in patients after myocardial
infarction (8-10) . These considerations, together with the
negative effect on survival caused by the administration of
traditional antiarrhythmic drugs (12,13), have given impetus
to the search for a mechanism to shift the autonomic balance
toward vagal predominance as a potential strategy in the
prevention of sudden cardiac death .
Low doses of atropine and other muscarinic antagonists
have been shown to produce paradoxic vagomimetic effects
(14,15) . Dibner-Dunlap et al . (16) observed that transdermal
administration of the muscarinic antagonist scopolamine in
healthy young men produced an increase in the mean RR
interval and its standard deviation (SD) and in the baro-
receptor response to graded neck suction . However, the
relevance of these data to patients after myocardial infarc-
tion is uncertain because patients with myocardial infarction
are older and show a transient impairment in vagal activity
(6,17,18) . Therefore, the goal of this study was to evaluate
the effects of transdermal scopolamine on indexes of vagal
tone and reflexes in patients shortly after myocardial infarc-
tion. Preliminary data have been presented elsewhere (19) .
0735-1097193IS6.00
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Methods
The study was performed in 20 randomly selected pa-
tients who gave informed consent to the study (one addi-
tional patient declined to take part in the study, and one did
not perform the study because of high blood pressure on the
day of the first test). Two subjects were women, and 18 were
men (mean age 59 ± 11 years, range 37 to 78 ; mean left
ventricular ejection fraction 52 ± 12%, range 29% to 68%0)
.
The infarction was anterior in 8 patients and inferior in 12
.
Exclusion criteria were age 80 years ; atrial fibrillation
or frequent atrial or ventricular arrhythmia that made anal-
ysis of sinus cycles impossible
; atrioventricular block ; his-
tory of insulin-dependent d',~ °tes mellitus and signs or
history of central or periphei .. nellropathy ; blood pressure
>160/100 mm Hg with diuretic gents; and serious, concom-
itant noncardiovascular disease, such as renal or hepatic
failure, Patients were also excluded if they had postinfarc-
tion angina, were directed tc card urgent mechanical or
surgical revascutarization or I . i heart failure unresponsive
to the sole administration of t : : iretic agents . Patients were
enrolled 8 to 15 days after myocardial infarction and were
studied during pharmacologic washout . Beta-adrenergic
blocking agents ; calcium channel antagonists ; vasodilators ;
antiarrhythmic, antidepressant and antihypertensive agents ;
nitrates, and any drug that could have interfered with the
autonomic assessment were withdrawn at least 5 half-lives
before the beginning of the study . No patient was receiving
digitalis . Diuretic agents were allowed, if needed, to control
blood pressure and pulmonary congestion . Platelet-active
and noncardiovascular drugs were also allowed and kept at
the same dosage throughout the study .
The protocol consisted of the assessment of heart rate
variability and baroreceptor reflex sensitivity in control
conditions, 24 h after the application of one patch of scopol-
amine (Transcop, Recordati) to the skin behind one car and
24 h after removal of the active compound patch and its
replacement with a placebo patch . The patients had no
knowledge of the treatment given . The active patch con-
tained 1 .5 mg of scopolamine and was designed for contin-
uous release of 0.5 mg every 24 h. Although most of the tests
in each patient were performed on 3 consecutive days,
occasionally > 1 day elapsed between two tests for logistic
reasons. However, the patch was always applied 24 h before
the evaluation. The test with scopolamine was performed
14 ± 3 days (range 10 to 18) after the occurrence of
myocardial infarction.
The test was always performed at the same time of day,
3 h after a light meal. Throughout the study, smoking and
eine-containing beverages were not allowed
. The pa-
tients were studied while supine at rest in a quiet, tempera-
ture-controlled room, and they were asked to relax and to
avoid talking and sleeping . The recording was started after
10 to 15 min of acclimation and lasted 15 min
. Heart rate
variability was assessed with a commercially available soft-
ware (Predictor, Corazonix)
. Analog electrocardiographic
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(ECG) signal was digitized at 500 Hz
. The QRS complex was
recognized by cross correlation with the template of the
normal QRS complex chosen by the investigator . Premature
atrial and ventricular beats and the subsequent interval were
excluded automatically by the analysis, and the automatic
detection was also visually checked by the investigator for
proper identification
. Time domain variables considered in
this study were the mean RR interval and its SD, the mean
squared successive difference and the percent of intervals
differing >50 ms from the preceding interval. Power spectral
analysis was performed by an autoregressive algorithm
(Predictor, Corazonix) with a direct current filter and model
order 16 . The boundaries of the low frequency (average 0 .05
to 0.16 Hz, with a peak at 0 .10 Hz) and high frequency
(average 0 .18 to 0 .42 Hz, with a peak at 0
.27 Hz) regions
were chosen manually for each test by an investigator
unaware of the treatment, and the area was automatically
obtained by the software . A very low frequency peak was
generally not revealed by the analysis
. A pilot study of the
reproducibility of the time domain measures (the SD of the
mean RR interval, the mean square successive difference
and the percent of intervals differing >50 ms from the
preceding interval) among two recordings t
:- 90 min from
each other, performed with this protocol in 10 patients,
shows a correlation (r value) from 0.974 to 0.982 .
Assessment of baroreceptor reflex sensitivity was per-
formed shortly after, according to the method of Smyth et al .
(20). Blood pressure was continuously monitored noninva-
sively by infrared digital plethysmography (Finapres 2300,
Ohmeda). `This signal and a lead 11 ECG signal were digitized
and fed into a Compaq 286 computer with custom-made
software (G . Plnna, PhD, Montescano, Italy) for analysis of
baroreceptor reflexes . The alpha,-agonist phenylephrine was
injected (initial dose 200 fag) for 30 s to obtain an increase in
blood pressure of 20 to 30 mm Hg . Baroreceptor reflex
sensitivity was calculated as the slope of the linear regres-
sion line relating systolic blood pressure changes to RR
interval changes . Regression lines with >_20 points and an
r ~ 0.70 were accepted for analysis . The phenylephrine
injection was repeated until three linear regressions with
these characteristics were obtained (in most cases this was
achieved with the first three injections). The average of these
three slopes was then taken as the baroreceptor reflex
sensitivity value . The average duration of the whole test
session was 80 min (range 70 to 100) .
Statistical analysis. Results are expressed, unless other-
wise stated, as mean value ± SD. Regression lines for
baroreceptor reflex sensitivity were calculated with the
least-squares method . Normality of the distributions was
assessed both graphically and with a goodness of fit test . The
overall difference among mean values in the three groups
(control, scopolamine, placebo) was evaluated with one-way
analysis of variance for repeated measures or with a
Kruskal-Wallis test for nonnormal distributions (percent of
intervals differing >50 ms from the preceding interval and
power spectral densities)
. A subsequent direct comparison
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was made, respectively, with a t test for paired samples or
with a Wilcoxon signed rank test . A p value < 0 .05 was
considered significant, with the exception of the multiple
comparisons among the three treatments, where the limit for
significance was set at p < 0 .017, according to the Bonfer-
roni correction .
Results
The scopolamine patch was well tolerated by the patients .
The sole side effects were dryness of mouth in one patient
and light-headedness in another patient . The latter patient
also reported a similar effect during the subsequent placebo
patch application. No other side effect was reported .
The overall technical quality of the tests was good . No
heart rate variability recording had to be discarded because
of excessive premature beats . The average correlation coef-
ficient of the baroreceptor slopes was 0 .85 t 0.08. Three
patients had on?, two acceptable regression slopes in one of
the two contre,l conditions. No major side effect was ob-
served after phenylephrine injection . Two patients reported
a mild transient flushing ; one had modest horripilation ; and a
few perceived the slowing of heart rate .
Heart rate vari?,Wfity. Analysis of variance for time do-
main variables derived from the 15-min recording of RR
intervals revealed significant differences in all of the vari-
ables (Fig. 1). The placebo patch did not induce any signif-
icant change in any of the variables .
Mean heart period (mean RR interval) during the scopol-
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Figure 1 . Effect of scopolamine and placebo on the mean sinus cycle
(RR), its standard deviation (StD), the mean squared successive
difference interval (MSSD) and the percent of sinus cycles differing
from the preceding cycle by >50 ms (PNN50) . Bars represent mean
value ± SEM for each variable . *Analysis of variance for repeated
measures for RR (p < 0 .002), SO (p < 0 .001) and MSSD (p < 0.001)
and the Kruskal-Wallis test for pNN50 (p < 0 .001) .
amine test was greater compared with both control (average
7.1%, p = 0.01) and placebo conditions (average 9 .9%, p =
0.0001). This effect on the RR interval corresponds to an
average decrease of 5 to 6 beats/min in heart rate . The SD of
the mean RR interval increased correspondingly more . Dur-
ing the scopolamine test, it was 25% greater than during the
control period (p = 0 .004) and 36% greater than during the
placebo period (p = 0.003) . This greater increase in the SD of
the mean RR interval, compared with that of the mean RR
interval, indicates that the increase in variabil ;ty was linked
only to a minor extent to the increase in mean heart cycle .
The mean squared successive difference among heart cycles
increased significantly during the scopolamine test compared
with both the control (by 38%, p = 0 .0003) and placebo
conditions (by 61%, p = 0 .0003). The percent of intervals
among sinus beats differing >50 ms from the previous
interval was significantly greater in the scopolamine test than
in the control or placebo trial (p = 0 .001 and p < 0.001,
respectively, by the Wilcoxon signed rank test) . Figure 2 is
an example of the heart period histogram of a patient during
control conditions ard after scopolamine .
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Analysis of the frequency domain variables (power spec-
trum density of the different areas) disclosed no overall
difference among the three groups in the total (0 to 0 .5 Hz)
spectral density or in the tow frequency component . A trend
toward a difference was noted for the high frequency com-
ponent (p = 0.06). The ratio of low and high frequency
components showed a significant difference among the three
groups (p < 0,05) . The placebo conditions had no effect on
this variable, whereas scopolamine induced a decrease that
was of borderline significance compared with the value
during control conditions (24%, p = 0.02) and was clearly
significant compared with that during placebo conditions
(p = 0.009) (Fig. 3). There was a moderate correlation
between measures of heart rate variability during control
conditions and after the scopolamine test (for the SD of the
mean RR interval, r = 0 .59, p = 0.005).
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Figure 3. Effect of scopolamine and placebo treatments on the ratio
of the areas in the low and high frequency bands of the power
spectrum (LFIHF) . Bars represent mean value ± SEM . *p < 0.05,
analysis of variance for repeated measures .
M .
CONTROL
Figure 2. Example of frequency (FREQ) histogram and
related time domain measures provided by the study
software in one patient during control conditions (upper
panel) and scopolamine treatment (lower panel) . In this
patient there was a very modest effect on the mean RR
interval (Mean) but a marked effect on the standard
deviation (StD) (1-63% the mean squared successive
difference (MSSD) (+74%) and the percent of sinus
cycles differing from the preceding cycle by >50 ms
(PNNSO) (+170%%). HR = heart rate . The software also
provides the total number of intervals that occurred
during the recording (Ints) ; the number of those accepted
for the analysis (Accpt), the duration of the shortest
(Short) and longest (Long) interval ; the frequency of
occurrence of the most common class of beats (MaxFrq),
according to the selected bin width (BinWd, in the
example IC ms) ; and the following statistical variables
obtained from the RR intervals (1111 STATS): the mode
and median (Mod) of the distribution ; the coefficient of
variance (CoVr) and the standard deviation of the 5-min
average normal to normal (NN) intervals (SDANN) .
SCOPOLAMINE
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Figure 4 . Effect of scopolamine and placebo treatments on the
baroreceptor reflex sensitivity (BRS) . Bars represent mean value
SEM . *p < 0 .001, analysis of variance for repeated measures .
Baroreceptor reflex sensitivity . Analysis of variance for
the baroreceptor reflex sensitivity disclosed I significant
difference among the three groups (p < 0 .001) . Similar to the
other variables analyzed, no difference was found between
control and placebo conditions (p = 0 .34). Scopolamine
increased baroreceptor reflex sensitivity by 42% compared
with control values (from 8 .1 ± 4.6 to 11 .5 ± 6.4 ms/mm Hg,
p = 0.0006). Baroreceptor reflex sensitivity was also signif-
icantly greater in the scopolamine test than during placebo
conditions (p = 0 .01) (Fig. 4). Figure 5 shows the good
correlation (r = 0 .84, p < 0 .001) between baroreceptor reflex
sensitivity at baseline and after scopolamine. Figure 5 (right)
identifies the patients with increased, and those few with
decreased, baroreceptor reflex sensitivity . Figure 6 is an
example of the linear regression of two baroreceptor reflex
sensitivity tests in one patient during control conditions and
after scopolamine .
Correlation of all of the variables studied with the age of
the patients was evaluated . This disclosed a moderate neg-
ative correlation between age and baroreceptor rcflcx sensi-
tivity (r = 0 .63, p < 0.005) and very modest negative
correlations between age and the SD of the mean RR
E
0
0
Figure 5 . Correlation between the
values of baroreceptor reflex sensi-
tivity (BRS) observed during control
conditions and scopolamine treat-
ment. Left, Linear regression shows
good correlation . Right, Solid circles
to the left and right of the identity line
y = x indicate itients whose barore-
ceptor reflex sensitivity increased
5~
and decreased, respectively .
10 1
0
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y=2.10+1 .09 x, r=0.84
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interval, the mean square successive difference and the
percent of intervals differing >50 ms from the preceding
interval (r = -0 .49 to -0.42, p = 0 .025 to 0 .06). No other
significant correlation was found . No correlation was found
between ejection fraction and the measures of vagal tone and
reflexes . No difference was also found during any study
conditions between patients with inferior versus anterior
myocardial infarction . However, it is possible that the ab-
sence of difference may be due to the relatively small sample
size of this study .
In the overall group of patients, scopolamine did not
cause significant changes in blood pressure (126 ± 17 vs .
132 ± 18 mm Hg during control conditions for systolic blood
pressure). The standard 12-lead ECG disclosed no significant
difference in the PR interval (172 ± 28 ms during control
conditions and 178 ± 24 ms during the scopolamine test) or
in QT interval corrected (QTc) for heart rate (QTc 420 ± 34
before and 412 ± 30 during the scopolamine test) . In one
patient, Wenckebach second-degree atrioventricular (AV)
block occurred during phenylephrine injection in two of four
scopolamine tests but in none of the control injections .
An echocardiographic evaluation was performed in nine
patients during both placebo and scopolamine administra-
tion, and no difference was found in either dimension or
function of the left ventricle (ejection fraction was 54 ± 12%
during control conditions and 53 ± 10% during scopolamine
treatment) .
Discussion
This study indicates that transdermal administration of
scopolamine significantly increases measures of heart rate
variability and baroreceptor reflex sensitivity in patients
with a recent myocardial infarction . These markers of vagal
tone and reflexes are shifted toward values associated with a
lower mortality in previous clinical studies (8-10). Pharma-
cologic modulation of the autonomic nervous system may
thus result in a shift of the sympathovagal balance toward a
1332
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6. Example of baroreceptor reflex sensitivity in one patient
during control conditions and after scopolamine treatment. Sensi-
tivity is expressed by the slope of the linear regression between
systolic blood pressure (absdm) and the subsequent RR interval
(ardhate) . In this patient, a marked increase in baroreceptor reflex
sensitivity was observed . The blood pressure increase during the
two tests was significantly greater than the average increase (20 to
30 mm ft but, as easily observed, the response was still linear
.
vagal dominance and may deserve evaluation as a new
approach in the prevention of sudden death after myocardial
infarction.
BackgrawW. Scopolamine has been shown to have vag-
omimetic effects in healthy young volunteers (16)
. However,
the possibility of a similar effect in patients after myocardial
infarction was uncertain because 1) the age range of the
subjects in the study by Dibner-Dunlap et al
. (16) (22 to 34
years, mean age 27) was completely different from that of
patients with myocardial infarction . Age exerts a consider-
able influence on markers of vagal activity and specifically
JACC Vol. 22 . No . 5
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on baroreceptor sensitivity (8,9,21) ; 2) myocardial infarction
creates a derangement of the autonomic balance, resulting in
an impairment of the parasympathetic component (6,17,18) .
Thus, the observation in healthy young adults cannot nec-
essarily predict the results in older subjects with myocardial
infarction . The finding that scopolamine may also increase
heart rate variability and baroreceptor reflex sensitivity in
patients shortly after myocardial infarction may have clinical
implications because higher values of both markers are
correlated with a better prognosis (8-10) .
Baseline findings . The baroreceptor reflex sensitivity in
this group of patients was very similar to that in a previous
study by our group (8) . Similar to that study, we found no
correlation between baroreceptor reflex sensitivity and ejec-
tion fraction, and a moderate negative correlation between
age and baroreceptor reflex sensitivity . A modest correlation
with age was also found for heart rate variability indexes .
The absence of a stronger correlation was expected because
the presence of myocardial infarction is likely to perturb the
relation between age and vagal effects .
Effects of scopolamine. The mean RR interval increased
after scopolamine administration by a value comparable to
that (13%) observed in healthy young men by Dibner-Dunlap
et al. (16) . The increase in SD was also similar to that in the
latter study (31%) despite the great difference in baseline
values (35 vs . 105 ms) . The findings are strengthened in this
study by the marked and significant effect of scopolamine on
two time domain variables considered as indexes of tonic
vagal activity to the heart (22) : the mean square successive
difference and the percent of intervals differing >50 ms from
the preceding interval . Among the patients with a SD of the
mean RR interval below the mean value of the whole group
(n = 10), o of 10 increased their heart rate variability, often
considerably. Therefore, the effect of scopolamine appears
to be particularly marked among patients considered to be at
higher risk .
Frequency domain analysis of heart rate provided a
further means to investigate the autonomic regulation of the
heart . The ratio of low frequency to high frequency spectral
densities has been proposed as an index of sympathovagal
balance (23) . The decrease in this ratio, observed in the
scopolamine test, indicates that the autonomic balance was
modified toward vagal predominance.
Vagal reflexes were also significantly increased 24 h after
application of the scopolamine patch . Baroreceptor reflex
sensitivity increased by 422% compared with control values .
More specifically, eight patients with a baseline baroreceptor
reflex sensitivity <6 ms/mm Hg showed an average increase
in sensitivity of 53%
; five patients with a baseline baro-
receptor reflex sensitivity <4 ms/mm Hg showed an average
increase of 74%
; and three patients with a baseline baro-
receptor re6exx sensitivity <3 ms/mm Hg showed an average
increase of 790/6 . This is an important point in the study
because it indicates that the effects of scopolamine were also
clearly present in patients considered to be at very high risk
(8,9) (i .e ., baroreceptor reflex sensitivity <3 ms/mm Hg) .
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Mechanisms. The first observation that low doses of
atropine cause a reduction in sinus rate was made as early as
1915 (14) . However, both central (24,25) and peripheral (26)
sites of action have been suggested, and a precise explana-
tion for this paradoxic vagomimetic effect is still lacking (27) .
Relevant here is the fact that, compared with most other
muscarinic antagonists, scopolamine has a greater central
effect (28) .
Characteristics and limitations of the study . Analysis of
heart rate variability was performed with relatively short
periods of recording so that the assessment could be coupled
with that of baroreceptor reflex sensitivity . The result was a
total duration of the test of <90 min that would not cause the
patient discomfort and thereby alter the results . This rela-
tively short duration makes a study of this type feasible as a
clinical tool, at least for selected patients, We decided not to
base our study on repeated Holter recordings because this
would have doubled the duration of the protocol owing to
the lag time for scopolamine absorption and the half-life of
the drug (16) . Moreover, it was possible to strictly control
the recording cots -litions, including recording time, room
temperature and isition and activity of the patients,
whereas these coi ., ions may vary widely during repeated
Hotter recordings and have a profound influence on heart
rate variability . Finally, stationary signals, such as those
obtained during controlled recording in this study, are better
suited for both time and frequency domain analysis (29) .
For of baroreceptor reflex sensitivity we
utilized noninvasive measurements with the digital plethys-
mographic technique . This technique has been validated for
continuous beat to beat blood pressure recording (30). A
preliminary analysis of the baroreceptor reflex sensitivity
values obtained with intraarterial methods and with Finapres
in 376 patients after myocardial infarction, as part of the
multicenter ATRAMI (Autonomic Tone and Reflexes After
Myocardial Infarction) study, shows very good correlation
(r = 0 .92 [311). On the basis of these results, the use of
noninvasive assessment of baroreceptor reflex sensitivity
was preferred, also because the measurements were re-
peated three times. Noninvasive blood pressure measure-
ment is clearly a less stressful condition for the patient
compared with intraarterial recording .
The absence of any significant difference between the
control and placebo conditions indicates that 1) the effect
was indeed due to scopolamine ; 2) no relevant spontaneous
change in vagal activity occurred during the period of the
study; 3) the effect was reversible ; and 4) the placebo patch
had no effect on the assessed variables. In addition, the
present results are in agreement with those of two similar
studies performed at the same time by two other groups
(32,33) .
This study enrolled unselected patients after myocardial
infarction. As a consequence, several patients had good
ventricular function and would thus be considered at low
risk by the traditional risk stratification criteria . However,
autonomic variables, notably baroreceptor reflex sensitivity,
DE FERRARI ET AL
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have no correlation with ejection fraction, and they appear
capable of identifying patients at very high risk also among
the subgroup with a very good ejection fraction (8,9) . We
decided to study patients without drugs for this preliminary
study, to avoid potentially confounding agents . However, it
will be useful to confirm these effects in patients taking their
routine drug treatment .
Potential clinical implications . Increasing evidence sug-
gests that vagomimetic interventions may decrease the like-
lihood of malignant arrhythmia in the setting of acute myo-
cardial ischemia (1-4) . Vagal nerve stimulation markedly
decreased the incidence of ventricular fibrillation (34) in a
conscious canine model for sudden cardiac death that com-
bined a previous myocardial infarction, elevated sympa-
thetic activity and transient myocardial ischemia (11). In the
sank experimental model, the muscarinic agonists rnetha-
choline and oxotremorine provided incomplete but signifi-
cant protection against sudden death (35) . These drugs, at
variance with the beta-blocker propranolol, were completely
devoid of negative inotropic effects (35) . Oxotremorine also
markedly decreased the incidence of life-threatening ventric-
ular arrhythmias induced in a feline model by the combina-
tion of acute myocardial ischemia and sympathetic hyper-
activity (36) . Thus, vagomimetic agents may represent an
interesting approach, particularly when beta-blockers are
contraindicated and when preservation of inotropism is
essential .
However, the potential clinical application of muscarinic
agonists must await the availability of compounds that
display acceptable selectivity for cardiac muscarinic (M 2 )
receptors (27) . Pharmacologic modulation of neural activity
with scopolamine may effectively increase vagal activity
with limited side effects and may thus deserve further
evaluation in the search for new strategies in the prevention
of sudden cardiac death after myocardial infarction .
We are grateful to Pinuccia De Tomasi for careful attention to the preparation
of the manuscript and to Riccardo Sarri for expert photographic support .
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